The Beatrice Hunter Cancer Research Institute logo
  • Dr. Alison Thompson, BSc, PhD

Appointments:

Full Professor, Faculty of Science Killam Professor 2012-2017

Affiliations:

Dalhousie University 

Research Interests:

Medicinal chemistry, organic synthesis, inorganic chemistry, biological activities of compounds

Organic and medicinal synthetic chemistry enables drug discovery and an understanding of biochemical processes that lead to disease

In the Thompson group we pride ourselves upon being synthetic organic chemists who use our skills to design and synthesise new compounds with interesting biological activities. In particular, we synthesise pyrrole-containing compounds and other analogues of the ubiquitous natural product prodigiosin. We work with collaborators, locally, nationally and internationally, to evaluate the therapeutic value of these compounds as novel treatments for a range of cancer types.

Membership Status:

Dr. Thompson is a BHCRI Senior Scientist and has been a member on a BHCRI Scientific Review Committee.

Phone:

(902) 494-3305

Email:

Alison.Thompson@dal.ca

Website:

www.dal.ca/faculty/science/chemistry/faculty-staff/our-faculty/alison-thompson.html

Address:

Department of Chemistry, Chemistry Building, Dalhousie University, PO BOX 15000, Halifax, Nova Scotia, B3H 4R2

Publications:

Synthesis of prodigiosene-estrogen conjugates: optimization of protecting group strategies and anticancer properties. Marchal, E.;Hawco, C.L.A.; Uddin, Md. I.; Thompson, A. Can. J. Chem., 2015, 93, 526-535 (CIHR, NSHRF, BHCRI/TFRI/CCNS/CRTP).
 
Influence of B-ring modifications on proton affinity, transmembrane anion transport and anti-cancer properties of synthetic prodigiosenes. Marchal, E.; Rastogi, S.; Thompson, A.; Davis, J.T. Org. Biomol. Chem., 2014, 12, 7517-7522 (CIHR, NSHRF, BHCRI/TFRI/CCNS/CRTP).
 
B-Ring Modifications, pKa and Transmembrane Transport of Prodigiosenes. Marchal, E.; Rastogi, S.; Thompson, A.; Jeffery T. Davis, J.T.; Org. Biomol. Chem., 2014, 12, 7515-22 (CIHR, NSHRF).
 
Antimicrobial activity of non-natural prodigiosenes. Marchal, E.; Uddin, Md. I.; Smithen, D.A.; Hawco, C.L.A.; Lanteigne, M.; Overy, D.P.; Kerr, R.G.; Thompson, A. RSC Adv. 2013, 3, 22967-22971 (BHCRI/TFRF/CCNS/CRTP/CIHR).

Synthesis and biological evaluation of prodigiosene conjugates of porphyrin, estrone and 4-hydroxytamoxifen. Hawco, C.L.A.; Marchal, E.; Uddin, Md. I.; Baker, A.E.G.; Corkery, D.P.; Dellaire, G.; Thompson, A. Bioorg. Med. Chem. 2013, 21, 5995-6002 (NSHRF/BHCRI/TFRI/ CCNS/CRTP).

Synthetic Prodigiosenes and the Influence of C-ring Substitution on DNA Cleavage, Transmembrane Chloride Transport and Basicity. Rastogi, S.; Marchal, E.; Uddin, Md. I.; Groves, B.; Colpitts, J.; McFarland, S.A.; Jeffery T. Davis, J.T.; Thompson, A. Org. Biomol. Chem., 2013, 11, 3834-3845 (CIHR, NSHRF, BHCRI/TFRI/CCNS/CRTP).

Conversion of F-BODIPYs to Cl-BODIPYs: Enhancing the Reactivity of F-BODIPYs. Lundrigan, T.; Thompson, A. J. Org. Chem. 2013, 78, 757-761.

Synthesis and Characterisation of the Unsubstituted Dipyrrin and 4,4-Dichloro-4-bora-3a,4a-diaza-s-indacene: Improved Synthesis and Functionalization of the Simplest BODIPY Framework. Groves, B.R.; Crawford, S.M.; Lundrigan, T.; Matta, C.F. Sowlati-Hashjin, S.; Thompson, A. ChemCommun. 2012, 49, 816-818.

Investigations Regarding the Utility of Prodigiosenes to Treat Leukemia. Thompson, A. Smithen, D.A.; Forrester, A.M.; Corkery, D.P.; Dellaire, G.; Colpitts, J.; McFarland, S.A.; Berman, J.N.; Thompson, A. Org. Biomol. Chem. 2013, 1, 62-68 plus cover art.

Synthesis of Heteroleptic Pyrrolide/Bipyridyl Complexes of Ruthenium(II). Lundrigan, T.; Jackson, C.L.M.; Uddin, Md. I.; Tucker, L.A.; Al-Sheikh Ali, A.; Linden, A.; Cameron, T.S.; Thompson, A. Can. J. Chem., 2012, 90, 693-700.

Site by: Spectacle Group